Juno shares surge on news of $1 billion payment from Celgene
UPDATE: Oracle sinks after hours on weak results
Celgene board approves additional $4 billion share buyback
UPDATE: CORRECTED: Celgene board approves additional $4 billion share buyback
Research and Markets: Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies
Research and Markets: Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
Tuttle Tactical Management, LLC is an investment adviser registered with the U.S. Securities and Exchange Commission. You should not assume that any discussion or information contained in this letter serves as the receipt of, or as a substitute for, personalized investment advice from Tuttle Tactical Management, LLC. It is published solely for informational purposes and is not to be construed as a solicitation nor does it constitute advice, investment or otherwise. To the extent that a reader has questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional adviser of his/her choosing. A copy of our written disclosure statement regarding our advisory services and fees is available upon request. Our comments are an expression of opinion. While we believe our statements to be true, they always depend on the reliability of our own credible sources. Past performance is no guarantee of ...
Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...
Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.
Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.